Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Blood Biomarkers to Detect Alzheimer Disease in Primary Care and Secondary Care
Sebastian Palmqvist, Pontus Tideman, Niklas Mattsson, et al.
JAMA (2024) Vol. 332, Iss. 15, pp. 1245-1245
Closed Access | Times Cited: 85

Showing 1-25 of 85 citing articles:

Head‐to‐head comparison of leading blood tests for Alzheimer's disease pathology
Suzanne E. Schindler, Kellen K. Petersen, Benjamin Saef, et al.
Alzheimer s & Dementia (2024) Vol. 20, Iss. 11, pp. 8074-8096
Open Access | Times Cited: 21
Second-generation anti-amyloid monoclonal antibodies for Alzheimer’s disease: current landscape and future perspectives
Byeong‐Hyeon Kim, Sujin Kim, Yunkwon Nam, et al.
Translational Neurodegeneration (2025) Vol. 14, Iss. 1
Open Access | Times Cited: 4
Cutting through the noise: A narrative review of Alzheimer's disease plasma biomarkers for routine clinical use
Michael Schöll, Agathe Vrillon, Takeshi Ikeuchi, et al.
The Journal of Prevention of Alzheimer s Disease (2025), pp. 100056-100056
Open Access | Times Cited: 2
Donanemab: Appropriate use recommendations
G D Rabinovici, D. J. Selkoe, Suzanne E. Schindler, et al.
The Journal of Prevention of Alzheimer s Disease (2025), pp. 100150-100150
Open Access | Times Cited: 2
Point of view: Challenges in implementation of new immunotherapies for Alzheimer's disease
Sandar Aye, Gunilla Johansson, Christoph Höck, et al.
The Journal of Prevention of Alzheimer s Disease (2025) Vol. 12, Iss. 1, pp. 100022-100022
Open Access | Times Cited: 1
Clinical utility of plasma p‐tau217 in identifying abnormal brain amyloid burden in an Asian cohort with high prevalence of concomitant cerebrovascular disease
Joyce R. Chong, Saima Hilal, Boon Yeow Tan, et al.
Alzheimer s & Dementia (2025)
Open Access | Times Cited: 1
Accuracy and clinical applicability of plasma tau 181 and 217 for Alzheimer’s disease diagnosis in a memory clinic cohort
Jordi Sarto, Diana Esteller-Gauxax, Núria Guillén, et al.
Journal of Neurology (2025) Vol. 272, Iss. 2
Closed Access | Times Cited: 1
Unlocking ocular biomarkers for early detection of Alzheimer's disease
Nikhil Dave, Melissa Lee, H Pavlou, et al.
Alzheimer s & Dementia (2025)
Open Access | Times Cited: 1
Lecanemab for early Alzheimer's disease: Appropriate use recommendations from the French federation of memory clinics
Nicolas Villain, Vincent Planche, Matthieu Lilamand, et al.
The Journal of Prevention of Alzheimer s Disease (2025), pp. 100094-100094
Open Access | Times Cited: 1
Blood-Based Biomarkers for Alzheimer Disease—Ready for Primary Care?
Lawren VandeVrede, Gil D. Rabinovici
JAMA Neurology (2024) Vol. 81, Iss. 10, pp. 1030-1030
Closed Access | Times Cited: 7
A comprehensive head-to-head comparison of key plasma phosphorylated tau 217 biomarker tests
Noëlle Warmenhoven, Gemma Salvadó, Shorena Janelidze, et al.
Brain (2024)
Open Access | Times Cited: 7
Alzheimer’s Disease: Exploring the Landscape of Cognitive Decline
Rumiana Tenchov, Janet M. Sasso, Qiongqiong Angela Zhou
ACS Chemical Neuroscience (2024) Vol. 15, Iss. 21, pp. 3800-3827
Open Access | Times Cited: 6
Aging-associated sensory decline and Alzheimer’s disease
Suji Hong, Seung Hyun Baek, Mitchell K.P. Lai, et al.
Molecular Neurodegeneration (2024) Vol. 19, Iss. 1
Open Access | Times Cited: 5
Advancements and challenges in mouse models of Alzheimer’s disease
Zhengjiang Qian, Yanjiao Li, Keqiang Ye
Trends in Molecular Medicine (2024)
Closed Access | Times Cited: 4
Clinical Utility of an Alzheimer’s Disease Blood Test Among Cognitively Impaired Patients: Results from the Quality Improvement PrecivityAD2 (QUIP II) Clinician Survey Study
Mark Monane, Demetrius M. Maraganore, Robert G. Carlile, et al.
Diagnostics (2025) Vol. 15, Iss. 2, pp. 167-167
Open Access
Blutbiomarker für Morbus Alzheimer

DMW - Deutsche Medizinische Wochenschrift (2025) Vol. 150, Iss. 03, pp. 73-73
Closed Access
Analytical Validation and Performance of a Blood-Based P-tau217 Diagnostic Test for Alzheimer Disease
Adam Abel, Antonio Chambers, Jeff A. Fill, et al.
The Journal of Applied Laboratory Medicine (2025)
Open Access
Blood Biomarkers to Detect Alzheimer Disease—Reply
Sebastian Palmqvist, Oskar Hansson
JAMA (2025)
Closed Access
Blood Biomarkers to Detect Alzheimer Disease
Yishai Mintzker
JAMA (2025)
Closed Access
AI-powered model for accurate prediction of MCI-to-AD progression
Ahmed Abdelhameed, Jingna Feng, Xinyue Hu, et al.
Acta Pharmaceutica Sinica B (2025)
Open Access
Guideline recommendations on the role of the general practitioner in the diagnosis of dementia: a protocol for a scoping review of clinical practice guidelines
Mary M. Cronin, Aisling Jennings, Marieke Perry, et al.
HRB Open Research (2025) Vol. 7, pp. 46-46
Open Access
White matter injury, plasma Alzheimer's disease, and neurodegenerative biomarkers on cognitive decline in community‐dwelling older adults: A 10‐year longitudinal study
Qili Hu, Xiaowen Zhou, Zhenxu Xiao, et al.
Alzheimer s & Dementia (2025) Vol. 21, Iss. 2
Open Access
Exploring cognitive and neuroimaging profiles of dementia subtypes of individuals with dementia in the Democratic Republic of Congo
Jean Ikanga, Saranya Sundaram, Megan Schwinne, et al.
Frontiers in Aging Neuroscience (2025) Vol. 17
Open Access
Clinical relevance of plasma ADAM-17 with cognition and neurodegeneration in Alzheimer's disease
Zu-Qi Chen, Meng Ting Wang, Cheng‐Rong Tan, et al.
Journal of Alzheimer s Disease (2025)
Closed Access
Blood N-glycomics reveals individuals at risk for cognitive decline and Alzheimer’s disease
Robin Ziyue Zhou, Stefan Gaunitz, Bjørn‐Eivind Kirsebom, et al.
EBioMedicine (2025) Vol. 113, pp. 105598-105598
Closed Access
Page 1 - Next Page

Scroll to top